全球重症肌无力疾病市场根据Polaris Market research发布的一项新研究，预计到2026年将超过25.386亿美元。2017年，就收入而言，诊断部门在全球市场占据主导地位。重症肌无力病的特点是在yabo官网入口人的自愿控制下，任何肌肉迅速疲劳和虚弱。尽管重症肌无力可以影响任何年龄的人，但它更常见于40岁以下的女性和60岁以上的男性。一般来说，重症肌无力是由肌肉和神经之间的正常通讯中断引起的。MG病尚无确切的治疗方法，但适当的早期治疗有助于控制症状，如复视、言语、咀嚼、吞咽和呼吸困难、手臂或腿部肌肉无力、眼睑下垂等。
全球Myasthenia Gravis Disease market is majorly driven by the need to prevent declining quality of life owing to myasthenia gravis disease. Moreover, growing R&D initiatives for novel therapies are another factor boosting the market growth. In addition, key players are also involved in innovative research to launch the affordable therapeutics for such disease. However, the unfamiliarity with early symptoms as well as signs and high cost associated with the treatment are factors hampering the market growth.
有问题吗？购买本报告前，请点击以下链接索取样品或进行查询：
//m.nkkjrh.com/industry-analysis/mysifia-gravis-disease-market
全球重症肌无力疾病市场is segmented on the basis of diagnosis, treatment, end-user, and region. On the basis of diagnosis, the market is categorized into Imaging, Blood Tests, Electrodiagnostic, and Edrophonium Test. The imaging segment is further bifurcated into X-ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others. On the basis of treatment, the market is segmented into Medication, Surgery, and HSCT. The end-user is further segmented in to Hospitals, Clinics, and Academic Research Institutes.
Geographically, North America accounted for the largest share in the global Myasthenia Gravis Disease Market in 2017. The major factors accounted for the high market growth includes high occurrence of disease such in North America. Moreover, Asia Pacific is estimated to generate the lucrative market growth during the forecast period. Growing initiatives by government and private organizations for generating novel control treatment are factors estimated to propel the myasthenia gravis disease market growth in Asia Pacific. In addition, increasing awareness about neuromuscular disorders and vast improvement are boosting the market growth in APAC.
《重症肌无力疾病市场报告》中介绍的主要公司包括亚历克赛制药公司、阿瓦德制药公司、CSL贝林公司、Grifols S.A.、巴克斯特国际公司、夏尔公司、诺华公司、F.霍夫曼拉罗什公司、武田制药有限公司，这些公司推出新产品，并与其他市场领导者合作创新和推出新产品，以满足消费者日益增长的需求和要求。